Clinical Trial Update: A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations [Phase 1, Phase 2]

View source ↗

Summary

A multicenter Phase 1b/2 trial is evaluating adagrasib, cetuximab, and cemiplimab for metastatic colorectal cancer harboring KRAS G12C mutations, with recruitme…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• ERBITUX (cetuximab)
• KRAZATI (adagrasib)
• Libtayo (cemiplimab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Colorectal Cancer, KRAS G12C Mutations | Phase 1, Phase 2 | Status: RECRUITING